scholarly journals OR07-04 A Novel Ex Vivo Live-Cell Interrogative Assay of Human Parathyroid Tissue Reveals Distinct Mechanisms of Calcium Sensing Failure in Primary, Secondary, and Tertiary Hyperparathyroidism

2020 ◽  
Vol 4 (Supplement_1) ◽  
Author(s):  
Jie Zhang ◽  
Run Zhang ◽  
Jessica Foft ◽  
Catherine Starks ◽  
Jessica Erin Gosnell ◽  
...  

Abstract Disruption of calcium homeostasis is common to all forms of hyperparathyroidism (HPT), but the underlying biochemical mechanisms that distinguish the various forms of HPT pathology remain poorly characterized. We previously have observed that the kinetics and amplitude of CASR-mediated signaling vary significantly among parathyroid (PT) adenomas and found specific functional and gene expression profiles preferentially associated with increased risk of bone density loss. While these data established a clear connection between CASR activity and clinical phenotype, a direct comparison of the kinetics of PTH secretory behavior between normal and neoplastic intact human PT tissue has yet to be performed. Utilizing eucalcemic normal human organ donor tissues (n=3) as a reference standard, we examined a series of cryopreserved live PT tissue specimens obtained from patients with primary (n=9), secondary (n=12) and tertiary (n=5) HPT. PT tissue fragments matched for viability, mass, and cellular content were placed on permeable membranes and exposed to a series of extracellular calcium concentrations over equivalent time intervals of challenge and normocalcemic recovery to interrogate dynamic PTH secretory induction or suppression. As expected, normal tissue exhibited a sigmoid response curve indicative of allosteric calcium-mediated inhibition, with a mean EC50 of 0.95 mM (95% CI: 0.859–1.254). In contrast, the majority of primary HPT adenomas (n=6) displayed a concave response curve indicative of non-competitive inhibition, consistent with a primary sensing deficit, such as loss of CASR expression. Two distinct PTH secretory behaviors were observed in secondary HPT specimens. One subset (secondary type 1, n=4) retained a sigmoid response curve but with a modest EC50 increase (mean EC50=1.50 mM, 95% CI: 1.41–1.61) and maximal suppression similar to normal tissue, features reflective of competitive inhibition in response to elevated calcium. This pattern could indicate enhanced CASR antagonist activity relative to normal tissue. A second subset, (secondary type 2, n=8) demonstrated a large EC50 shift (mean EC50=2.46 mM; 95% CI: 1.844–2.621), a sigmoid response curve, and an elevated threshold of persistent PTH secretion at high calcium conditions. These parameters are suggestive of non-competitive inhibitory behavior, consistent with loss of a CASR-dependent downstream effector. Three of the primary HPT adenomas shared this response phenotype. Of the tertiary specimens, four matched the primary HPT adenoma pattern, while one exhibited secondary type 2 behavior. These results reveal a series of progressively attenuated dynamic response patterns, where PTH secretion becomes increasingly uncoupled from extracellular calcium sensing. These findings suggest that primary, secondary, and tertiary HPT arise through distinct mechanisms of calcium sensing failure.

2020 ◽  
Vol 4 (Supplement_1) ◽  
Author(s):  
Anna K Gluck ◽  
Mark Stevenson ◽  
Sara Falcone ◽  
Asuka Inoue ◽  
Gerda E Breitwieser ◽  
...  

Abstract The G-protein subunits Gα 11 and Gα q, which share >90% peptide sequence identity and are encoded by the GNA11 and GNAQ genes, respectively, mediate signalling by the calcium-sensing receptor (CaSR), a class C G-protein coupled receptor (GPCR) that regulates extracellular calcium (Ca2+e) homeostasis. Germline Gα 11 inactivating and activating mutations cause familial hypocalciuric hypercalcaemia type-2 (FHH2) and autosomal dominant hypocalcaemia type-2 (ADH2), respectively, but such Gα q mutations have not been reported. We therefore investigated the DiscovEHR cohort database, which has exomes from 51,289 patients with matched phenotyping data, for such GNAQ mutations. The DiscovEHR cohort was examined for rare GNAQ variants, which were transiently expressed in CaSR-expressing HEK293A Gα q/11 knockout cells, and their effects on CaSR-mediated intracellular calcium (Ca2+i) release and MAPK activity, in response to increasing concentrations of extracellular calcium were assessed using a nuclear factor of activated T-cells response element (NFAT-RE) luciferase reporter construct and a serum response element (SRE) luciferase reporter construct, respectively. Responses were compared to those of wild-type (WT), inactivating FHH2-associated GNA11 mutations (Leu135Gln and Phe220Ser), and engineered GNAQ mutations that were equivalent to the FHH2-causing GNA11 mutations. Gα q/11 protein expression was confirmed by Western blot analysis. Six rare missense GNAQ variants (Arg19Trp, Ala110Val, Gln299His, Ala302Ser, Ala331Thr, Val344Ile) were identified in DiscovEHR individuals, all of whom had mean plasma calcium values in the normal range (8.30–10.00 mg/dL). Functional characterisation of all six Gα q variants showed no significant difference to WT Gα q responses, thereby indicating that these variants are unlikely to be disease-causing mutations. In addition, the FHH2-causing GNA11 mutations (Leu135Gln and Phe220Ser) had significantly reduced responses, compared to WT Gα 11; however, this could be compensated by WT Gα q. GNAQ Leu135Gln and Phe220Ser, in contrast to their Gα 11 counterparts, showed no differences in protein expression or signalling responses when compared to WT Gα q. Our study, which provides mechanistic insights into the differences between Gα q and Gα 11, indicates that Gα q, unlike Gα 11, does not play a major role in the pathogenesis of FHH2 or ADH2.


Metabolites ◽  
2021 ◽  
Vol 11 (1) ◽  
pp. 58 ◽  
Author(s):  
Michael D. Schaid ◽  
Yanlong Zhu ◽  
Nicole E. Richardson ◽  
Chinmai Patibandla ◽  
Irene M. Ong ◽  
...  

The transition from β-cell compensation to β-cell failure is not well understood. Previous works by our group and others have demonstrated a role for Prostaglandin EP3 receptor (EP3), encoded by the Ptger3 gene, in the loss of functional β-cell mass in Type 2 diabetes (T2D). The primary endogenous EP3 ligand is the arachidonic acid metabolite prostaglandin E2 (PGE2). Expression of the pancreatic islet EP3 and PGE2 synthetic enzymes and/or PGE2 excretion itself have all been shown to be upregulated in primary mouse and human islets isolated from animals or human organ donors with established T2D compared to nondiabetic controls. In this study, we took advantage of a rare and fleeting phenotype in which a subset of Black and Tan BRachyury (BTBR) mice homozygous for the Leptinob/ob mutation—a strong genetic model of T2D—were entirely protected from fasting hyperglycemia even with equal obesity and insulin resistance as their hyperglycemic littermates. Utilizing this model, we found numerous alterations in full-body metabolic parameters in T2D-protected mice (e.g., gut microbiome composition, circulating pancreatic and incretin hormones, and markers of systemic inflammation) that correlate with improvements in EP3-mediated β-cell dysfunction.


Sign in / Sign up

Export Citation Format

Share Document